Building Strategic Relationships with CROs

How to adopt win-win strategies and understand quality agreements for complying with cGMP when building strategic relationships with pharmaceutical contract research organizations.

Pharmaceutical and biopharmaceutical companies have been extensively using contract research organizations (CROs) to meet their challenging needs in R&D and standard work for several decades. A noticeable shift occurred in outsourcing research and clinical work when Big Pharma R&D costs skyrocketed. For example, in 2012, approximately 33% of drugs in the pipelines of the top 10 pharmaceutical companies were initially developed elsewhere (1).

Read this article in BioPharm International’s Outsourcing Resources February 2020 eBook.

Article Details

BioPharm International
Outsourcing Resources eBook
February 2020
Pages: s20–s23

Citation

When referring to this article, please cite it as S. Karmarkar, “Building Strategic Relationships with CROs,” in BioPharm International Outsourcing Resources eBook (February 2020).

Articles in this issue

over 5 years ago

Article

Lyophilization Services Gain Ground Amid Growing Biologics Market

over 5 years ago

Article

Biopharma Contract Market Update

over 5 years ago

Article

Digitalization: A CDMO’s Perspective

over 5 years ago

Article

More Capacity and Technology Translate to More Options

over 5 years ago

Article

Sourcing Success in Cell and Gene Therapy Development

over 5 years ago

Article

Using the “Cubic Effect” to Drive Cell and Gene Therapy Commercialization

over 5 years ago

Article

Growth in Biologics Market Inspires Outsourcing

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!